AT CES 2019, Evolucare, associated with ADCIS, enters into an exclusive and global licence agreement with SATT Ouest Valorisation, a french technology transfert office, and AP-HP Paris Hospitals.
Evolucare, an essential SME in the hospital information system, and ADCIS, another SME and a specialist of image processing and analysis, both proudly announced on Thursday, January 10, the execution of an exclusive worldwide license agreement with SATT Ouest Valorisation and AP-HP at CES (Consumer Electronics Show) 2019 in Las Vegas. Member of the French HealthTech delegation led by SATT (Technology Transfer Accelerator Offices), the partners seize a unique opportunity to promote internationally a long-term partnership for the automated screening of diabetic retinopathy and in the near future, other eye pathologies. The innovation, called OphtAI, is an Artificial Intelligence that is the outcome of 3 years of collaborative research between researchers, clinicians and industrials. Embedded in the Evolucare tele-ophthalmology and imaging platform, OphtAI will enable better care for nearly half a billion people at risk worldwide.
For more information, click here.